A STRATEGY FOR BUSINESS DIVERSIFICATION AND GEOGRAPHIC EXPANSION . Laboratoire Cerba, at the origin of the Cerba HealthCare Group, was established in 1967. Performing clinical pathology services on behalf of other public and private laboratories across the globe, it has rapidly become a global reference in specialised clinical pathology. The year 2007 marks the beginning of the diversification of the Group's activities and geographical position. 1967 – 2007 Actor in specialised clinical pathology and anatomocytopathology 1967: Creation of Laboratoire Cerba 1998: Merger with the Centre de Biologie Médicale Spécialisée [Specialised Clinical Pathology Centre] of Institut Pasteur, an expert in infectious diseases 1998: COFRAC accreditation according to the standard ISO/ IEC 17025: Cerba becomes the first private accredited laboratory in France 2000: Cerba creates the first clinical pathology training organisation for healthcare professionals 2015: Creation of the Institut Cerba endowment fund 2016: Launch of Cerba HealthCare University 2016: Cerba is the first private laboratory to perform whole exome sequencing and become active in the diagnosis of rare constitutional genetic diseases 2012: Laboratoire Cerba becomes the first private French laboratory to obtain a high-throughput sequencer and to offer, as of 2013, the NIPD test, a non-invasive prenatal diagnostic for trisomies 13, 18 and 21 on foetal DNA 2013: Launch of Biopredix, the first range of preventive medicine check-ups to preserve health capital 2020: Creation of Cerba Path, an entity that brings together anatomical pathology and cytology activities in France 2021: Acquisition of LifeBrain in Italy and Labexa in France Acquisition of ViroclinicsDDL, a specialist in clinical trials in virology and immunology 2022: Creation of the Group's CSR Department and publication of its first CSR report 2007 Geographic and business diversification: Routine clinical pathology and clinical pathology for clinical trials in Belgium 2009 – 2014 Geographic and business diversification: Routine clinical pathology in France and in Luxembourg 2015 – 2016 Business diversification: Veterinary clinical pathology 2017 – 2019 Geographic and business diversification: Routine clinical pathology in Italy and Africa and medical imaging in Italy 2020 – 2021 COVID-19: Key player in screening and epidemiology Consolidation of market positioning in routine clinical pathology in France 2018: Creation of the Cerba Vet College, a training organisation for veterinarians 2019: Launch of Innov Lab, the Group's ideas platform 8 THE GROUP AND ITS CSR STRATEGY
RkJQdWJsaXNoZXIy NzMxNTcx